460 related articles for article (PubMed ID: 23652165)
81. Guillain-Barré syndrome following influenza vaccination: A 15-year nationwide population-based case-control study.
Levison LS; Thomsen RW; Andersen H
Eur J Neurol; 2022 Nov; 29(11):3389-3394. PubMed ID: 35913431
[TBL] [Abstract][Full Text] [Related]
82. Did the influenza A (H1N1) 2009 monovalent inactivated vaccines increase the risk for Guillain-Barré syndrome?
Salmon DA; Vellozzi C; Chen RT; Halsey NA
Expert Rev Clin Immunol; 2013 Sep; 9(9):795-7. PubMed ID: 24070041
[No Abstract] [Full Text] [Related]
83. Postvaccination Miller Fisher syndrome.
Shoamanesh A; Chapman K; Traboulsee A
Arch Neurol; 2011 Oct; 68(10):1327-9. PubMed ID: 21987549
[TBL] [Abstract][Full Text] [Related]
84. Events temporarily associated with anti-influenza A (H1N1) vaccination in Mexico.
Vidal P; Reyna J; Saldaña P; Richardson VL
Arch Med Res; 2011 Oct; 42(7):627-32. PubMed ID: 22036935
[TBL] [Abstract][Full Text] [Related]
85. Estimating background rates of Guillain-Barré Syndrome in Ontario in order to respond to safety concerns during pandemic H1N1/09 immunization campaign.
Deeks SL; Lim GH; Simpson MA; Rosella L; Mackie CO; Achonu C; Crowcroft NS
BMC Public Health; 2011 May; 11():329. PubMed ID: 21586163
[TBL] [Abstract][Full Text] [Related]
86. Post-Campylobacter Guillain Barré Syndrome in the USA: secondary analysis of surveillance data collected during the 2009-2010 novel Influenza A (H1N1) vaccination campaign.
Halpin AL; Gu W; Wise ME; Sejvar JJ; Hoekstra RM; Mahon BE
Epidemiol Infect; 2018 Oct; 146(13):1740-1745. PubMed ID: 29986777
[TBL] [Abstract][Full Text] [Related]
87. Guillain-Barre syndrome after vaccination in United States a report from the CDC/FDA Vaccine Adverse Event Reporting System.
Souayah N; Nasar A; Suri MF; Qureshi AI
Vaccine; 2007 Jul; 25(29):5253-5. PubMed ID: 17560693
[TBL] [Abstract][Full Text] [Related]
88. Guillain-Barré syndrome in the United States, 1979-1980 and 1980-1981. Lack of an association with influenza vaccination.
Kaplan JE; Katona P; Hurwitz ES; Schonberger LB
JAMA; 1982 Aug; 248(6):698-700. PubMed ID: 7097920
[TBL] [Abstract][Full Text] [Related]
89. Letter to the Editor. Guillain-Barré Syndrome(GBS) after vaccination reported to the United States Vaccine Adverse Event Reporting System(VAERS) in 2004.
Haber P; Slade B; Iskander J
Vaccine; 2007 Nov; 25(48):8101. PubMed ID: 17933441
[No Abstract] [Full Text] [Related]
90. Guillain-Barré syndrome after Gardasil vaccination: data from Vaccine Adverse Event Reporting System 2006-2009.
Souayah N; Michas-Martin PA; Nasar A; Krivitskaya N; Yacoub HA; Khan H; Qureshi AI
Vaccine; 2011 Jan; 29(5):886-9. PubMed ID: 20869467
[TBL] [Abstract][Full Text] [Related]
91. Values for preventing influenza-related morbidity and vaccine adverse events in children.
Prosser LA; Bridges CB; Uyeki TM; Rêgo VH; Ray GT; Meltzer MI; Schwartz B; Thompson WW; Fukuda K; Lieu TA
Health Qual Life Outcomes; 2005 Mar; 3():18. PubMed ID: 15780143
[TBL] [Abstract][Full Text] [Related]
92. Immunization-safety monitoring systems for the 2009 H1N1 monovalent influenza vaccination program.
Salmon DA; Akhtar A; Mergler MJ; Vannice KS; Izurieta H; Ball R; Lee GM; Vellozzi C; Garman P; Cunningham F; Gellin B; Koh H; Lurie N;
Pediatrics; 2011 May; 127 Suppl 1():S78-86. PubMed ID: 21502251
[TBL] [Abstract][Full Text] [Related]
93. Signals and trends of Guillain-Barré syndrome after the introduction of live-attenuated vaccines for influenza in the US and South Korean adverse event reporting systems.
Lee H; Kim HJ; Choe YJ; Shin JY
Vaccine; 2020 Jul; 38(34):5464-5473. PubMed ID: 32600907
[TBL] [Abstract][Full Text] [Related]
94. A prospective observational safety study on MF59(®) adjuvanted cell culture-derived vaccine, Celtura(®) during the A/H1N1 (2009) influenza pandemic.
Reynales H; Astudillo P; de Vallière S; Hatz C; Schlagenhauf P; Rath B; Velentgas P; Fariña A; Sales-Carmona V; Groth N
Vaccine; 2012 Oct; 30(45):6436-43. PubMed ID: 22902681
[TBL] [Abstract][Full Text] [Related]
95. Effectiveness of H1N1/09 monovalent and trivalent influenza vaccines against hospitalization with laboratory-confirmed H1N1/09 influenza in Australia: a test-negative case control study.
Cheng AC; Kotsimbos T; Kelly HA; Irving LB; Bowler SD; Brown SG; Holmes M; Jenkins CR; Thompson P; Simpson G; Wood-Baker R; Senanayake SN; Brady SJ; Paterson DL; Wark PA; Upham JW; Korman TM; Dwyer DE; Waterer GW; Kelly PM
Vaccine; 2011 Oct; 29(43):7320-5. PubMed ID: 21810450
[TBL] [Abstract][Full Text] [Related]
96. Neurological and autoimmune disorders after vaccination against pandemic influenza A (H1N1) with a monovalent adjuvanted vaccine: population based cohort study in Stockholm, Sweden.
Bardage C; Persson I; Ortqvist A; Bergman U; Ludvigsson JF; Granath F
BMJ; 2011 Oct; 343():d5956. PubMed ID: 21994316
[TBL] [Abstract][Full Text] [Related]
97. [Guillain-Barré syndrome after exposure to influenza].
Hartung HP; Keller-Stanislawski B; Hughes RA; Lehmann HC
Nervenarzt; 2012 Jun; 83(6):714-30. PubMed ID: 22528062
[TBL] [Abstract][Full Text] [Related]
98. The reporting sensitivity of the Vaccine Adverse Event Reporting System (VAERS) for anaphylaxis and for Guillain-Barré syndrome.
Miller ER; McNeil MM; Moro PL; Duffy J; Su JR
Vaccine; 2020 Nov; 38(47):7458-7463. PubMed ID: 33039207
[TBL] [Abstract][Full Text] [Related]
99. Guillain-Barre syndrome after influenza vaccine administration: two adult cases.
Bedard Marrero V; Osorio Figueroa RL; Vázquez Torres O
Bol Asoc Med P R; 2010; 102(2):39-41. PubMed ID: 20939203
[TBL] [Abstract][Full Text] [Related]
100. Safety of Influenza A H1N1pdm09 Vaccines: An Overview of Systematic Reviews.
Juvet LK; Robertson AH; Laake I; Mjaaland S; Trogstad L
Front Immunol; 2021; 12():740048. PubMed ID: 34777351
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
